<DOC>
	<DOCNO>NCT02363868</DOCNO>
	<brief_summary>The purpose study examine healthcare cost among patient CML receive dasatinib nilotinib first line therapy commercially Medicare insured population .</brief_summary>
	<brief_title>Healthcare Costs Among Patients With CML Receiving Dasatinib Nilotinib Commercial Medicare Population</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Age &gt; 18 year International Classification Diseases , Ninth Revision , Clinical Modification ( ICD9 CM ) code CML ( 205.1x ) At least 2 prescription dasatinib nilotinib July 1 , 2008 June 31 , 2013 Continuous eligibility 6 month pre postindex date ( defined date first fill dasatinib nilotinib ) History bone marrow stem cell transplant identify 6 month preperiod</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>